Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231GFP breast cancer cells in vitro and on osteolytic lesions induced in vivo by this cell line in nude rats

Clinical and Experimental Metastasis

Volumn 24, Issue 6, 2007, Pages 449-459

  Peterschmitt, Jenny ^a   Bäuerle, Tobias ^a   Berger, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anti BSPII antibody; Bone sialoprotein II; MDA MB 231 human breast cancer cell line; Nude rat model; Osteolytic bone metastasis; Zoledronic acid

Indexed keywords

BONE SIALOPROTEIN; BONE SIALOPROTEIN 2 ANTIBODY; GREEN FLUORESCENT PROTEIN; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEFECT; BONE LESION; BONE MINERALIZATION; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; FEMORAL ARTERY; HUMAN; HUMAN CELL; MALE; NONHUMAN; NUDE RAT; RADIOGRAPHY; RAT;

ANIMALS; ANTIBODIES; BREAST NEOPLASMS; CELL LINE, TUMOR; DIPHOSPHONATES; GREEN FLUORESCENT PROTEINS; HUMANS; IMIDAZOLES; MALE; OSTEOLYSIS; RATS; RATS, NUDE; SIALOGLYCOPROTEINS;

EID: 34548386684     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9082-x     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Taylor Murray, Xu J, Smigal C, Thun MJ (2006) Cancer statistics 2006. CA Cancer J Clin 56:106-130
2. Lipton A (2003) Bisphosphonates and metastatic breast carcinoma. Cancer 97(3Suppl):848-853
3. Clohisy DR, Manthy PW (2003) Bone cancer pain. Cancer 97(3):866-873
4. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nature 2:584-593
5. Rogers MJ, Watts DJ, Russell RGG (1997) Overview of bisphosphonates. Cancer 80(8):1652-1660
6. Green JR (2002) Bisphosphonates in cancer therapy. Current opinion in oncology 14:609-615
7. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97(3Suppl):840-847
8. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SRD (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327:469
9. Yoneda T, Michigami T, Bing Y, Williams PJ, Niewolna M, Hiraga T (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88:2979-2988
10. Hiraga T, Ueda A, Tamura D, Hata K, Ikeda F, Williams PJ, Yoneda T (2003) Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 106:973-979
11. Bellahcène A, Menard S, Bufalino R, Moreau L, Castronovo V (1996) Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69:350-353
12. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstorfer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker of subsequent bone metastasis. Clin Cancer Res 5:3914-3919
13. Zhang JH, Tang J, Wang J, Ma W, Zheng W, Yoneda T, Chen J (2003) Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncology 23:1043-1048
14. Adwan H, Bäuerle T, Najajreh Y, Elazer V, Golomb G, Berger MR (2004) Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncology 24:1235-1244
15. Bäuerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR (2005) Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer sells, and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 115:177-186
16. Bäuerle T, Peterschmitt J, Hilbig H, Kiessling F, Armbruster FP, Berger MR (2006) Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. Int J Oncology 28:573-583
17. Lundberg BB (1997) Ether lipids enhance the cytotoxic effect of teniposide and paclitaxel in liposomes against leukemic cells in culture. Anti-Cancer Drug Design 12:503-513
18. Dunn OJ (1964) Multiple comparison using rank sums. Technometrics 6:241-252
19. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2000) Structure-activity relationships for inhibition of farnesyl diphosphonate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242
20. Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, Séronie-Vivien S (2006) Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6:60
21. Jagdev SP, Coleman RE, Shipman CM, et al (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126-1134
22. Senaratne SG, Pirianov G, Mansi JL, et al (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459-1468
23. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 50(4):219-244
24. Bartl R (2002) Bisphosphonate. MANUAL Multiples Myelom 146-158
25. Phadke PA, Mercer RR, Harms JF, Jia Y, Frost AR, Jewell JL, Bussard KM, Nelson S, Moore C, Kappes JC, Gay CV, Mastro AM, Welch DR (2006) Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res 12(5):1431-1440